Leveraging human genetics to decipher B cell activation dysregulation in lupus
NIAID - National Institute of Allergy and Infectious Diseases
About This Grant
PROJECT SUMMARY The overarching goal of this research is to elucidate the genetic underpinnings of B cell activation dysregulation in lupus, a leading cause of morbidity among youth in the United States. By decoding the complex interactions at the genetic and cellular levels, this project aims to unveil new targets for therapeutic intervention, ultimately reducing the disease burden. The genetic contribution to lupus is high and genome-wide association studies (GWAS) have found >150 risk variants for lupus. However, linking GWAS risk variants to mechanism has been achieved for only a small proportion of loci given most of the likely causal variants are non-coding. Our preliminary data identified a relevant B cell activation condition at which a great proportion of lupus risk variants are likely exerting their regulatory effects. We have further preliminary data focused on 2 specific lupus risk loci, representing two classes of mechanisms by non-coding risk variants: one class that affects gene expression levels of the target gene, and one that affects isoform usage of the target gene. For each locus we plan to establish the most likely causal risk variant, the mechanism by which the risk allele causes dysregulation, and the function of the target gene in B cell differentiation. We plan to study these aspects in both healthy subjects and lupus patients, and by utilizing advanced technologies including single cell profiling, CRISPR methods, tonsil organoids and long read RNA sequencing. Furthermore, we plan to uncover additional loci with differential isoform usage driven by lupus risk loci. Overall, this research is poised to provide critical insights into the molecular mechanisms of lupus, offering potential strategies for targeted treatment. By enhancing our understanding of B cell biology in the context of chronic autoimmune disease, our findings could lead to the prioritization of novel genetic targets, laying the groundwork for innovative therapeutic approaches in lupus and other immune-mediated diseases.
Grant Summary
Leveraging human genetics to decipher B cell activation dysregulation in lupus is a NIAID - National Institute of Allergy and Infectious Diseases grant providing up to $906K for university, nonprofit, healthcare org. Applications are due 2031-04-30 (open). Check eligibility and apply with FindGrants.
Focus Areas
Eligibility
How to Apply
Up to $906K
2031-04-30
- 1Confirm your organization is eligible for Leveraging human genetics to decipher B cell activation dysregulation in lupus from NIAID - National Institute of Allergy and Infectious Diseases, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIAID - National Institute of Allergy and Infectious Diseases before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIAID - National Institute of Allergy and Infectious Diseases's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Leveraging human genetics to decipher B cell activation dysregulation in lupus: Frequently Asked Questions
Who is eligible for the Leveraging human genetics to decipher B cell activation dysregulation in lupus?
Leveraging human genetics to decipher B cell activation dysregulation in lupus is offered by NIAID - National Institute of Allergy and Infectious Diseases and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Leveraging human genetics to decipher B cell activation dysregulation in lupus provide?
Leveraging human genetics to decipher B cell activation dysregulation in lupus provides up to $906K per award from NIAID - National Institute of Allergy and Infectious Diseases. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Leveraging human genetics to decipher B cell activation dysregulation in lupus deadline?
Applications for Leveraging human genetics to decipher B cell activation dysregulation in lupus are due 2031-04-30 (open). Because deadlines can change, verify the date with the funder, NIAID - National Institute of Allergy and Infectious Diseases, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Leveraging human genetics to decipher B cell activation dysregulation in lupus?
To apply for Leveraging human genetics to decipher B cell activation dysregulation in lupus, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIAID - National Institute of Allergy and Infectious Diseases.